Back to results
US 2003/0153618 A1Published application
Treatment and prevention of herpes simplex infections
OwnerLarry Ford, Diane Fordinventors
Life of this patent
Estimating the term…
Abstract
We have discovered that the topical application of the amino acid lysine and the 6-methyl derivative of lysine to Herpes simplex virus Type II is therapeutically beneficial and relieves the discomfort and symptoms of HSV infections and prevents or reduces the number of severity of HSV infections. We have also discovered that derivatives of lysine, in addition to 6-methyl lysine and derivatives of arginine have an inhibitory effect upon HSV replication. These compounds are useful in the prevention and treatment of HSV lesions.
Claims3
Chemical compounds combinations suitable for treatment of vaginal herpes simplex disease comprising:
- a physically inert carrier suppository composition which is solid at room temperature and fluid at human body temperature;
- and
- a 0.01 to 5.0 wt % concentration of an amino acid selected from the class consisting of
- 31
- wherein none, one, two or three of R1, R2, R3 and R4 is methyl, hydroxyl, one to four carbon containing aliphatic ester, one to four carbon containing aliphatic ether and all others of said R1, R2, R3 and R4 are hydrogen, R5 is hydrogen, methyl, ethyl, carbamyl, isopropyl, isopropenyl, hydroxyl, one to four carbon containing aliphatic ester, one to four carbon containing aliphatic ether, or acetimidoyl, and R6 is hydrogen, methyl, acetyl, or carbamyl;
- or
- 32
- wherein none, one, two or three of R7, R8, R9 and R10 is methyl, hydroxyl, one to four carbon containing aliphatic ester, or one to four carbon containing aliphatic ether and all others of said R7, R8, R9 and R10 are hydrogen, R11 ism ethyl, acetyl, isopropyl, isopropenyl, hydroxyl, one to four carbon containing aliphatic ester, or one to four carbon containing aliphatic ether, acetimidoyl, and R12 is hydrogen, methyl, acetyl or carbamyl, or
- 33
6 more elements
Chemical compound combination suitable for treatment of herpes simplex disease comprising:
- a water soluble physiologically inert compatible base, and
- a 0.01 to 5.0 wt % concentration of an amino acid selected from the class of consisting of
- 34
- wherein none, one, two or three of R1, R2, R3 and R4 is methyl, hydroxyl, one to four carbon containing aliphatic ester, one to four carbon containing aliphatic ether and all others of said R1, R2, R3 and R4 are hydrogen, R5 is hydrogen, methyl, ethyl, carbamyl, isopropyl, isopropenyl, hydroxyl, one to four carbon containing aliphatic ester, one to four carbon containing aliphatic ether, or acetimidoyl, and R6 is hydrogen, methyl, acetyl, or carbamyl;
- or
- 35
- wherein none, one, two or three of R7, R8, R9 and R10 is methyl, hydroxyl, one to four carbon containing aliphatic ester, or one to four carbon containing aliphatic ether and all others of said R7, R8, R9 and R10 are hydrogen, R11 is methyl, acetyl, isopropyl, isopropenyl, hydroxyl, one to four carbon containing aliphatic ether, acetimidoyl, and R12 is hydrogen, methyl, acetyl or carbamyl;
- or
- 36
6 more elements
A process for treating herpes simplex disease infection of humans comprising:
- applying a composition of a water soluble physiologically inert compatible base;
- and
- a 0.01 to 5.0 wt % concentration of an amino acid selected from the class consisting of
- 37
- wherein none, one, two or three of R1, R2, R3 and R4 is methyl, hydroxyl, one to four carbon containing aliphatic ester, one to four carbon containing aliphatic ether and all others of said R1, R2, R3 and R4 are hydrogen, R5 is hydrogen, methyl, ethyl, carbamyl, isopropyl, isopropenyl, hydroxyl, one to four carbon containing aliphatic ester, one to four carbon containing aliphatic ether, or acetimidoyl, and R6 is hydroge n, methyl, acetyl, or carbamyl;
- or
- 38
- wherein none, one, two or three of R7, R8, R9 and R10 is methyl, hydroxyl, one to fur carbon containing aliphatic ester, or one to four carbon containing aliphatic ether and all others of said R7, R8, R9 and R10 are hydrogen, R11 is methyl, acetyl, isopropyl, isopropenyl, hydroxyl, one to four carbon containing aliphatic ester, or one to four carbon containing aliphatic ether, acetimidoyl, and R12 is hydrogen, methyl, acetyl or carbamyl;
- or
- 39
- wherein none, one, two or three of R13, R14, R15 and R16 is methyl, hydroxyl, one to four carbon containing aliphatic ester, or one to four carbon containing aliphatic ether and none or one of R13, R14, R15 and R16 is imino, all others of said R13, R14, R15 and R16 being hydrogen, and R18 is hydrogen, methyl, acetyl or carbamyl;
- or
- 40
- wherein none, one or two of R20, R21 and R22 is methyl, hydroxyl, one to four carbon containing aliphatic ester, or one to four carbon containing aliphatic ether, all others of R20, R21 and R22 being hydrogen, R23 is hydrogen, methyl, acetyl, carbamyl, isopropyl, hydroxyl, one to four carbon containing aliphatic ester, or one to four carbon containing aliphatic ether or isopropenyl, and R24 is hydrogen, methyl, acetyl or carbamyl;
- or
- 41
- wherein none, one, two or three of R30, R32 and R33 is methyl, hydroxyl, one to four carbon containing aliphatic ester, or one to four carbon containing aliphatic ether, or amino, all others of R31, R32, R33 being hydrogen, R34 is hydrogen, methyl, acetyl, amino, carbamyl, isopropyl, hydroxyl, one to four carbon containing aliphatic ester, or one to four carbon containing aliphatic ether, or isopropenyl, and R35 is hydrogen, methyl, acetyl or carbamyl;
- or
- 42
- wherein none, one, two or three of R40, R41 and R42 is methyl, hydroxyl, one to four carbon containing aliphatic ester, or one to four carbon containing aliphatic ether and all others of said R40, R41 and R42 are hydrogen, R43 is hydrogen, methyl, ethyl, carbamyl, isopropyl, isopropenyl, hydroxyl, one to four carbon containing aliphatic ether, or acetimidoyl, and R44 is hydrogen, methyl, acetyl, or carbamyl.
17 more elements
Dependencies are inferred from the claim text.